Open for inclusion

A Phase 1b Study to Evaluate safety and clinical activity of Pembrolizumab (MK-3475) in combination with Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) – (KEYNOTE 173)

Cancer type: Breast cancer

Phase: I

Principal Investigator: Foukakis Theodoros

Country: SE

Keywords: Sweden, Karolinska, TNBC, Neoadjuvant, Pembrolizumab

Status: Inclusion completed

Link to